10-Q · May 7, 2026
Rockwell Medical experienced a decline in revenue and EPS for Q1 2026, reporting $17.3 million in revenue, down 8% from $18.9 million in Q1 2025, with an EPS of -$0.04. The company emphasized an operational pivot…
Earnings analysis · 10-Q
RMTI earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The provided extract is limited to Part II and does not include the income statement, balance sheet, cash flow statement, segment results, or MD&A; therefore, revenue, margins, EPS, liquidity, and free-cash-flow trends…
Read full summary
The provided extract is limited to Part II and does not include the income statement, balance sheet, cash flow statement, segment results, or MD&A; therefore, revenue, margins, EPS, liquidity, and free-cash-flow trends cannot be assessed from the filing text supplied. Management reported effective disclosure controls as of June 30, 2026 and no material changes to internal controls. No material changes were reported to the risk factors from the 2025 Form 10-K, and no quantitative guidance was provided.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026.
-
No material control changes
The company reported no changes in internal control over financial reporting during the period covered by the report that materially affected, or were reasonably likely to materially affect, those controls.
-
CEO adopts 10b5-1 sale plan
A Rule 10b5-1 trading arrangement adopted by CEO Mark Strobeck covers 12,250 shares, with a stated duration from October 1, 2026 through July 3, 2028, subject to earlier completion.
-
Market-risk disclosure exemption
As a Smaller Reporting Company, Rockwell Medical is not required to provide the market-risk disclosures under Item 3 pursuant to Regulation S-K Section 229.305.
What to watch
-
Existing 10-K risks remain applicable
The company states that there have been no material changes to the risk factors in its 2025 Form 10-K, so the existing risk profile remains applicable through June 30, 2026.
-
Routine legal proceedings
Rockwell says it may be involved in routine legal proceedings, cannot predict their final disposition, and does not expect resolution to have a material effect on operations or consolidated financial statements in the period resolved.
-
Planned insider share sales
The CEO’s Rule 10b5-1 arrangement provides for the sale of 12,250 shares beginning October 1, 2026 and potentially continuing through July 3, 2028, which could create incremental equity-sale pressure.
Management's outlook
The provided 10-Q text contains no quantitative revenue or EPS outlook. Numeric guidance is therefore not provided in this filing.
Earlier filings 4
10-K · March 26, 2026
Rockwell Medical (RMTI) remained focused on its hemodialysis concentrates business in 2025 but experienced a meaningful revenue decline versus 2024 while making product and customer gains. Management added a…
10-Q · August 14, 2025
Rockwell Medical reported Q2 net sales of $16,071 (in thousands) and a GAAP diluted loss per share of $(0.05). Revenue declined materially vs. both the prior quarter and prior year, compressing gross margin to 15.6% and…
10-K · March 20, 2025
Rockwell Medical (RMTI) has refocused on its hemodialysis concentrates business (dialysate concentrates accounted for 100% of 2024 revenue) and expanded distribution via multiple agreements and the July 2023 Evoqua…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.